Manuela Gili

583 total citations
6 papers, 464 citations indexed

About

Manuela Gili is a scholar working on Neurology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Manuela Gili has authored 6 papers receiving a total of 464 indexed citations (citations by other indexed papers that have themselves been cited), including 2 papers in Neurology, 2 papers in Pulmonary and Respiratory Medicine and 2 papers in Oncology. Recurrent topics in Manuela Gili's work include HER2/EGFR in Cancer Research (2 papers), Neuroblastoma Research and Treatments (2 papers) and Neurofibromatosis and Schwannoma Cases (2 papers). Manuela Gili is often cited by papers focused on HER2/EGFR in Cancer Research (2 papers), Neuroblastoma Research and Treatments (2 papers) and Neurofibromatosis and Schwannoma Cases (2 papers). Manuela Gili collaborates with scholars based in Spain, Austria and Switzerland. Manuela Gili's co-authors include Sarat Chandarlapaty, José Baselga, Yasir H. Ibrahim, Sarai Rodríguez, Sharat Singh, B. Markman, Michelangelo Russillo, Joaquı́n Arribas, Ludmila Prudkin and Maurizio Scaltriti and has published in prestigious journals such as Oncogene, Journal of Medical Genetics and Human Mutation.

In The Last Decade

Manuela Gili

6 papers receiving 454 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Manuela Gili Spain	4	328	190	106	54	53	6	464
Karl Hsu United States	7	255 0.8×	168 0.9×	80 0.8×	82 1.5×	26 0.5×	14	433
P. LoRusso United States	12	229 0.7×	143 0.8×	84 0.8×	43 0.8×	34 0.6×	38	328
Woody Han United States	6	188 0.6×	141 0.7×	77 0.7×	52 1.0×	25 0.5×	8	345
Angelina T. Regua United States	10	184 0.6×	195 1.0×	97 0.9×	84 1.6×	35 0.7×	14	364
Kai Habben Germany	9	285 0.9×	230 1.2×	152 1.4×	121 2.2×	89 1.7×	13	536
Rik de Wijn Netherlands	9	182 0.6×	113 0.6×	58 0.5×	52 1.0×	36 0.7×	21	322
Megan M. Starr United States	4	181 0.6×	180 0.9×	98 0.9×	45 0.8×	57 1.1×	4	335
A. Barnadas Spain	10	179 0.5×	244 1.3×	88 0.8×	83 1.5×	84 1.6×	27	419
Søren M. Johnson United States	5	192 0.6×	174 0.9×	101 1.0×	47 0.9×	29 0.5×	5	391
Jennie Hauser United States	9	332 1.0×	235 1.2×	85 0.8×	94 1.7×	38 0.7×	13	542

Countries citing papers authored by Manuela Gili

Since Specialization

Citations

This map shows the geographic impact of Manuela Gili's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuela Gili with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuela Gili more than expected).

Fields of papers citing papers by Manuela Gili

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manuela Gili. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuela Gili. The network helps show where Manuela Gili may publish in the future.

Co-authorship network of co-authors of Manuela Gili

This figure shows the co-authorship network connecting the top 25 collaborators of Manuela Gili. A scholar is included among the top collaborators of Manuela Gili based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manuela Gili. Manuela Gili is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Gnant, Michael, Manuela Gili, Magdalena Schwarz, et al.. (2024). The future of clinical trials—goals, ideas, and discussion. memo - Magazine of European Medical Oncology. 17(2). 77–86. 3 indexed citations

2.

Rinnerthaler, Gabriel, Daniel Egle, Rupert Bartsch, et al.. (2023). 123O Randomized phase II trial of neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in early HER2-positive breast cancer (ABCSG-52/ATHENE). ESMO Open. 8(1). 101462–101462. 2 indexed citations

3.

Serra, Violeta, Maurizio Scaltriti, Ludmila Prudkin, et al.. (2011). PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 30(22). 2547–2557. 433 indexed citations

4.

Serra, Eduard, Eva Pros, Eva López, et al.. (2007). Tumor LOH analysis provides reliable linkage information for prenatal genetic testing of sporadic NF1 patients. Genes Chromosomes and Cancer. 46(9). 820–827. 4 indexed citations

5.

Pros, Eva, Sara Larriba, Eva López, et al.. (2006). NF1mutation rather than individual genetic variability is the main determinant of theNF1-transcriptional profile of mutations affecting splicing. Human Mutation. 27(11). 1104–1114. 16 indexed citations

6.

Antiñolo, Guillermo, et al.. (1997). Genotype-phenotype relationship in 12 patients carrying cystic fibrosis mutation R334W.. Journal of Medical Genetics. 34(2). 89–91. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact